Tiziana Life Sciences (TLSA) Liabilities and Shareholders Equity (2017 - 2025)

Tiziana Life Sciences' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $11.5 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 1.87% year-over-year to $11.5 million; the TTM figure through Dec 2025 stood at $50.3 million (down 2.91% YoY), while the FY2025 annual figure was $11.5 million, up 1.87% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $11.5 million, down from $16.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $58.6 million in Q2 2021, with the low at $11.0 million in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $17.0 million (2023), against an average of $24.9 million.
• The sharpest annual moves came in 2021 and 2023: Liabilities and Shareholders Equity jumped 349.85% in 2021, then slumped 53.98% in 2023.
• Tiziana Life Sciences' Liabilities and Shareholders Equity stood at $48.8 million in 2021, then tumbled by 45.77% to $26.5 million in 2022, then plunged by 53.98% to $12.2 million in 2023, then decreased by 7.39% to $11.3 million in 2024, then rose by 1.87% to $11.5 million in 2025.
• Business Quant data shows TLSA's Liabilities and Shareholders Equity at $11.5 million in Q4 2025, $16.6 million in Q2 2025, and $11.3 million in Q4 2024.